Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomics.


Journal

Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648

Informations de publication

Date de publication:
07 May 2024
Historique:
received: 22 08 2023
accepted: 25 03 2024
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 7 5 2024
Statut: aheadofprint

Résumé

Proteomics is making important contributions to drug discovery, from target deconvolution to mechanism of action (MoA) elucidation and the identification of biomarkers of drug response. Here we introduce decryptE, a proteome-wide approach that measures the full dose-response characteristics of drug-induced protein expression changes that informs cellular drug MoA. Assaying 144 clinical drugs and research compounds against 8,000 proteins resulted in more than 1 million dose-response curves that can be interactively explored online in ProteomicsDB and a custom-built Shiny App. Analysis of the collective data provided molecular explanations for known phenotypic drug effects and uncovered new aspects of the MoA of human medicines. We found that histone deacetylase inhibitors potently and strongly down-regulated the T cell receptor complex resulting in impaired human T cell activation in vitro and ex vivo. This offers a rational explanation for the efficacy of histone deacetylase inhibitors in certain lymphomas and autoimmune diseases and explains their poor performance in treating solid tumors.

Identifiants

pubmed: 38714896
doi: 10.1038/s41587-024-02218-y
pii: 10.1038/s41587-024-02218-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
ID : FKZ161L0214A
Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
ID : FKZ031L0168
Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
ID : FKZ031L0168
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 325871075
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 325871075

Informations de copyright

© 2024. The Author(s).

Références

Singh, S., Malik, B. K. & Sharma, D. K. Molecular drug targets and structure based drug design: a holistic approach. Bioinformation 1, 314–320 (2006).
pubmed: 17597912 pmcid: 1891708 doi: 10.6026/97320630001314
Meissner, F., Geddes-McAlister, J., Mann, M. & Bantscheff, M. The emerging role of mass spectrometry-based proteomics in drug discovery. Nat. Rev. Drug Discov. 21, 637–654 (2022).
pubmed: 35351998 doi: 10.1038/s41573-022-00409-3
Geoffrey, M. C. Pharmacology, part 1: introduction to pharmacology and pharmacodynamics. J. Nucl. Med. Technol. 46, 81 (2018).
doi: 10.2967/jnmt.117.199588
Swinney, D. C. Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discov. 3, 801–808 (2004).
pubmed: 15340390 doi: 10.1038/nrd1500
Tonge, P. J. Drug-target kinetics in drug discovery. ACS Chem. Neurosci. 9, 29–39 (2018).
pubmed: 28640596 doi: 10.1021/acschemneuro.7b00185
Backus, K. M. et al. Proteome-wide covalent ligand discovery in native biological systems. Nature 534, 570–574 (2016).
pubmed: 27309814 pmcid: 4919207 doi: 10.1038/nature18002
Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007).
pubmed: 17721511 doi: 10.1038/nbt1328
Liu, Y., Patricelli, M. P. & Cravatt, B. F. Activity-based protein profiling: the serine hydrolases. Proc. Natl Acad. Sci. USA 96, 14694–14699 (1999).
pubmed: 10611275 pmcid: 24710 doi: 10.1073/pnas.96.26.14694
Patricelli, M. P. et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46, 350–358 (2007).
pubmed: 17209545 doi: 10.1021/bi062142x
Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, eaan4368 (2017).
pubmed: 29191878 pmcid: 6542668 doi: 10.1126/science.aan4368
Sharma, K. et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741–744 (2009).
pubmed: 19749761 doi: 10.1038/nmeth.1373
Gaetani, M. et al. Proteome integral solubility alteration: a high-throughput proteomics assay for target deconvolution. J. Proteome Res. 18, 4027–4037 (2019).
pubmed: 31545609 doi: 10.1021/acs.jproteome.9b00500
Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 1255784 (2014).
pubmed: 25278616 doi: 10.1126/science.1255784
Van Vranken, J. G., Li, J., Mitchell, D. C., Navarrete-Perea, J. & Gygi, S. P. Assessing target engagement using proteome-wide solvent shift assays. eLife 10, e70784 (2021).
pubmed: 34878405 pmcid: 8654358 doi: 10.7554/eLife.70784
Zhang, X. et al. Solvent-induced protein precipitation for drug target discovery on the proteomic scale. Anal. Chem. 92, 1363–1371 (2020).
pubmed: 31794197 doi: 10.1021/acs.analchem.9b04531
Strickland, E. C. et al. Thermodynamic analysis of protein-ligand binding interactions in complex biological mixtures using the stability of proteins from rates of oxidation. Nat. Protoc. 8, 148–161 (2013).
pubmed: 23257983 doi: 10.1038/nprot.2012.146
Lomenick, B. et al. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl Acad. Sci. USA 106, 21984–21989 (2009).
pubmed: 19995983 pmcid: 2789755 doi: 10.1073/pnas.0910040106
Schopper, S. et al. Measuring protein structural changes on a proteome-wide scale using limited proteolysis-coupled mass spectrometry. Nat. Protoc. 12, 2391–2410 (2017).
pubmed: 29072706 doi: 10.1038/nprot.2017.100
Zecha, J. et al. Decrypting drug actions and protein modifications by dose- and time-resolved proteomics. Science 380, 93–101 (2023).
pubmed: 36926954 pmcid: 7615311 doi: 10.1126/science.ade3925
Pan, C., Olsen, J. V., Daub, H. & Mann, M. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol. Cell Proteom. 8, 2796–2808 (2009).
doi: 10.1074/mcp.M900285-MCP200
Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437–1452 e1417 (2017).
pubmed: 29195078 pmcid: 5990023 doi: 10.1016/j.cell.2017.10.049
Mitchell, D. C. et al. A proteome-wide atlas of drug mechanism of action. Nat. Biotechnol. 41, 845–857 (2023).
pubmed: 36593396 doi: 10.1038/s41587-022-01539-0
Ruprecht, B. et al. A mass spectrometry-based proteome map of drug action in lung cancer cell lines. Nat. Chem. Biol. 16, 1111–1119 (2020).
pubmed: 32690943 doi: 10.1038/s41589-020-0572-3
Saei, A. A. et al. ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery. Nat. Commun. 10, 5715 (2019).
pubmed: 31844049 pmcid: 6915695 doi: 10.1038/s41467-019-13582-8
Hughes, C. S. et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat. Protoc. 14, 68–85 (2019).
pubmed: 30464214 doi: 10.1038/s41596-018-0082-x
Bian, Y. et al. Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS/MS. Nat. Commun. 11, 157 (2020).
pubmed: 31919466 pmcid: 6952431 doi: 10.1038/s41467-019-13973-x
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
pubmed: 19029910 doi: 10.1038/nbt.1511
Gessulat, S. et al. Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning. Nat. Methods 16, 509–518 (2019).
pubmed: 31133760 doi: 10.1038/s41592-019-0426-7
Wilhelm, M. et al. Mass-spectrometry-based draft of the human proteome. Nature 509, 582–587 (2014).
pubmed: 24870543 doi: 10.1038/nature13319
Datta, J., Ghoshal, K., Motiwala, T. & Jacob, S. T. Novel insights into the molecular mechanism of action of DNA hypomethylating agents: role of protein kinase C δ in decitabine-induced degradation of DNA methyltransferase 1. Genes Cancer 3, 71–81 (2012).
pubmed: 22893792 pmcid: 3415671 doi: 10.1177/1947601912452665
Ercikan-Abali, E. A. et al. Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region. Biochemistry 36, 12317–12322 (1997).
pubmed: 9315871 doi: 10.1021/bi971026e
Uzor, S. et al. Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention. Gene 670, 46–54 (2018).
pubmed: 29802995 doi: 10.1016/j.gene.2018.05.095
Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682–690 (2008).
pubmed: 18936753 doi: 10.1038/nchembio.118
Bruno, P. M. et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat. Med. 23, 461–471 (2017).
pubmed: 28263311 pmcid: 5520548 doi: 10.1038/nm.4291
Demichev, V. et al. dia-PASEF data analysis using FragPipe and DIA-NN for deep proteomics of low sample amounts. Nat. Commun. 13, 3944 (2022).
pubmed: 35803928 pmcid: 9270362 doi: 10.1038/s41467-022-31492-0
Schwanhausser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337–342 (2011).
pubmed: 21593866 doi: 10.1038/nature10098
Zecha, J. et al. Peptide level turnover measurements enable the study of proteoform dynamics. Mol. Cell Proteom. 17, 974–992 (2018).
doi: 10.1074/mcp.RA118.000583
Sievers, Q. L. et al. Defining the human C
pubmed: 30385546 pmcid: 6326779 doi: 10.1126/science.aat0572
Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. eLife 7, e38430 (2018).
pubmed: 30067223 pmcid: 6156078 doi: 10.7554/eLife.38430
Hamminger, P., Rica, R. & Ellmeier, W. Histone deacetylases as targets in autoimmune and autoinflammatory diseases. Adv. Immunol. 147, 1–59 (2020).
pubmed: 32981634
Borcoman, E. et al. HDAC inhibition to prime immune checkpoint inhibitors. Cancers 14, 66 (2021).
pubmed: 35008230 pmcid: 8750966 doi: 10.3390/cancers14010066
Jiang, W. et al. Exhausted CD8
pubmed: 33633741 pmcid: 7902023 doi: 10.3389/fimmu.2020.622509
Mueller, S. N. & Ahmed, R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 106, 8623–8628 (2009).
pubmed: 19433785 pmcid: 2688997 doi: 10.1073/pnas.0809818106
Utzschneider, D. T. et al. Early precursor T cells establish and propagate T cell exhaustion in chronic infection. Nat. Immunol. 21, 1256–1266 (2020).
pubmed: 32839610 doi: 10.1038/s41590-020-0760-z
Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492–499 (2011).
pubmed: 21739672 doi: 10.1038/ni.2035
Eckert, S. et al. Evaluation of disposable trap column nanoLC-FAIMS-MS/MS for the proteomic analysis of FFPE tissue. J. Proteome Res. 20, 5402–5411 (2021).
pubmed: 34735149 pmcid: 7612824 doi: 10.1021/acs.jproteome.1c00695
The, M., Samaras, P., Kuster, B. & Wilhelm, M. Reanalysis of ProteomicsDB using an accurate, sensitive, and scalable false discovery rate estimation approach for protein groups. Mol. Cell. Proteom. 21, 100437 (2022).
doi: 10.1016/j.mcpro.2022.100437
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16, 284–287 (2012).
pubmed: 22455463 pmcid: 3339379 doi: 10.1089/omi.2011.0118
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2
pubmed: 11846609 doi: 10.1006/meth.2001.1262
Berg, S. et al. ilastik: interactive machine learning for (bio)image analysis. Nat. Methods 16, 1226–1232 (2019).
pubmed: 31570887 doi: 10.1038/s41592-019-0582-9
Lechner, S. et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat. Chem. Biol. 18, 812–820 (2022).
pubmed: 35484434 pmcid: 9339481 doi: 10.1038/s41589-022-01015-5
Prokofeva, P. et al. Merits of diazirine photo-immobilization for target profiling of natural products and cofactors. ACS Chem. Biol. 17, 3100–3109 (2022).
pubmed: 36302507 pmcid: 9680877 doi: 10.1021/acschembio.2c00500
Reinecke, M. et al. Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors. Nat. Chem. Biol. https://doi.org/10.1038/s41589-023-01459-3 (2023).

Auteurs

Stephan Eckert (S)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.
German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and University Center Technical University of Munich, Munich, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Nicola Berner (N)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.
German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and University Center Technical University of Munich, Munich, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Karl Kramer (K)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.

Annika Schneider (A)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.

Julian Müller (J)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.

Severin Lechner (S)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.

Sarah Brajkovic (S)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.

Amirhossein Sakhteman (A)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.

Christian Graetz (C)

Chair of Animal Physiology and Immunology, School of Life Sciences, Technical University of Munich, Freising, Germany.

Jonas Fackler (J)

Institute of Molecular Immunology and Experimental Oncology, School of Medicine and Health, Technical University of Munich, Munich, Germany.

Michael Dudek (M)

Institute of Molecular Immunology and Experimental Oncology, School of Medicine and Health, Technical University of Munich, Munich, Germany.

Michael W Pfaffl (MW)

Chair of Animal Physiology and Immunology, School of Life Sciences, Technical University of Munich, Freising, Germany.

Percy Knolle (P)

Institute of Molecular Immunology and Experimental Oncology, School of Medicine and Health, Technical University of Munich, Munich, Germany.

Stephanie Wilhelm (S)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany.

Bernhard Kuster (B)

Chair of Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, Freising, Germany. kuster@tum.de.
German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and University Center Technical University of Munich, Munich, Germany. kuster@tum.de.

Classifications MeSH